RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
First Claim
Patent Images
1. A composition comprising an interfering RNA having a sense and an antisense strand, wherein each strand is 19-49 nucleotides in length, wherein the sense strand comprises the RNA sequence of SEQ ID NO:
- 3, and a pharmaceutically acceptable carrier, and wherein the interfering RNA is an siRNA that inhibits HIF1A.
3 Assignments
0 Petitions
Accused Products
Abstract
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
-
Citations
1 Claim
-
1. A composition comprising an interfering RNA having a sense and an antisense strand, wherein each strand is 19-49 nucleotides in length, wherein the sense strand comprises the RNA sequence of SEQ ID NO:
- 3, and a pharmaceutically acceptable carrier, and wherein the interfering RNA is an siRNA that inhibits HIF1A.
Specification